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SHORT COMMUNICATION

Deﬁciency of Kruppel-like factor KLF4 in myeloid-derived
suppressor cells inhibits tumor pulmonary metastasis in mice
accompanied by decreased ﬁbrocytes
Y Shi1,2, L Ou2,3, S Han4, M Li5, MMO Pena6, EA Pena7, C Liu8, M Nagarkatti2, D Fan9 and W Ai2
The importance of immunosuppressive myeloid-derived suppressor cells (MDSCs) bearing monocyte markers in tumor metastasis
has been well established. Recently, it was reported that these cells possess phenotypic plasticity and differentiate into ﬁbrocytes,
very distinct cells that are precursors of tumorigenic myoﬁbroblasts. However, the importance of this transdifferentiation in
tumor metastasis has not been explored. Here, we describe the role of MDSC-derived ﬁbrocytes in tumor metastasis that is regulated
by Kruppel-like factor 4 (KLF4), a transcription factor that is critical to monocyte differentiation and to promotion of cancer
development. Using mouse metastasis models of melanoma and breast cancer, we found that KLF4 knockout was associated with
signiﬁcantly reduced pulmonary metastasis, which was accompanied by decreased populations of MDSCs, ﬁbrocytes and
myoﬁbroblasts in the lung. Cause-effect studies by adoptive transfer revealed that KLF4 deﬁciency in MDSCs led to signiﬁcantly
reduced lung metastasis that was associated with fewer MDSC-derived ﬁbrocytes and myoﬁbroblasts. Mechanistically, KLF4
deﬁciency signiﬁcantly compromised the generation of ﬁbrocytes from MDSCs in vitro. During this process, KLF4 expression levels
were tightly linked with those of ﬁbroblast-speciﬁc protein-1 (FSP-1), deﬁciency of which resulted in no metastasis in mice as has
been previously reported. In addition, KLF4 bound directly to the FSP-1 promoter as determined by chromatin immunoprecipitation
and overexpression of KLF4 increased the FSP-1 promoter activities. Taken together, our results suggest that MDSCs not only execute
their immunosuppressive function to promote metastatic seeding as reported before, but also boost metastatic tumor growth after
they adopt a ﬁbrocyte fate. Therefore, KLF4-mediated ﬁbrocyte generation from MDSCs may represent a novel mechanism of MDSCs
contributing to tumor metastasis and supports the feasibility of inhibiting KLF4 or FSP-1 to prevent tumor metastasis.
Oncogenesis (2014) 3, e129; doi:10.1038/oncsis.2014.44; published online 24 November 2014

INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) are a bone marroworiginated heterogeneous population of immature myeloid cells
with phenotypic plasticity1 and involved in multiple inﬂammatory
conditions.2,3 They are broadly deﬁned as CD11b+Gr-1+ or
CD11b+Ly6G+ cells in mice, with a wider range of markers in
humans. Increased MDSCs are associated with tumor growth and
metastasis in both tumor-bearing mice and cancer patients,4
which makes this population a novel therapeutic target.5 Recently,
MDSCs were found to be differentiated into ﬁbrocytes,6 a
very distinct cell type that may promote tumorigenesis by
incorporating into the tumor stromal and differentiating into
myoﬁbroblasts.7,8 In addition, expansion of ﬁbrocytes has
been observed in the microenvironment of solid tumors9 and
circulation of subjects with metastatic cancer,10 which facilitate
tumor metastasis.11 However, the importance and the underlying
molecular mechanism of MDSCs transdifferentiation into
ﬁbrocytes in tumor metastasis have not been clearly elucidated.
Kruppel-like factor 4 (KLF4) is a transcription factor12 critical to
monocyte differentiation,13 and has an oncogenic function in

cancer development.14,15 Recently, we found that KLF4 deﬁciency
in mammary tumor cells compromised the recruitment and
function of MDSCs in primary and metastatic tumors, resulting in
attenuated tumor development.16 However, whether and how
KLF4 in MDSCs, a major component of immunosuppressive cells in
tumor microenvironment,17 regulates tumor metastasis has not
been reported before.
In this study, we found that KLF4 deﬁciency in mice led to
reduced pulmonary metastasis, which was accompanied by
decreased populations of a subset of MDSCs bearing features of
CCR2+CD11b+Ly6Gint (CCR2+ MDSCs) and reduced numbers of
ﬁbrocytes and myoﬁbroblasts in the lung. Cause-effect studies
indicated that KLF4 deﬁciency in CCR2+ MDSCs was responsible for
compromised lung metastasis. Mechanistically, KLF4 regulated the
ﬁbrocyte generation from CCR2+ MDSCs in vitro and occupied the
ﬁbroblast-speciﬁc protein-1 (FSP-1) promoter, which may contribute
to increased promoter activities. Taken together, our study
demonstrates a critical role of KLF4-mediated ﬁbrocyte generation
from CCR2+MDSCs in tumor metastasis, which may provide a
therapeutic strategy to treat metastasis by targeting KLF4 or FSP-1.
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RESULTS AND DISCUSSION
KLF4 deﬁciency in mouse bone marrow drastically reduced lung
metastasis that was accompanied by decreased recruitment of
CCR2+ MDSCs in the lung
We recently reported that mammary tumor cell-expressing KLF4
facilitated primary tumor growth and pulmonary metastasis.16 The
accumulation of MDSCs in bone marrow, spleen and primary
tumors were all decreased in mice that were inoculated with breast
cancer cells lacking KLF4 expression. However, KLF4 deﬁciency is
restricted to tumor cells in this study, and the effect of KLF4 in
MDSCs on tumor metastasis still remains unknown. Therefore, we
generated inducible KLF4-knockout mice (Rosa26CreER/KLF4
(ﬂox+/+) mice on C57BL/6 background) and spontaneous KLF4knockout mice (FSP-1-Cre/KLF4 (ﬂox+/+) mice on BalB/c background). The efﬁciency of KLF4 knockout in both models was
conﬁrmed by quantitative reverse transcriptase–PCR indicating
that KLF4 expression in bone marrow was decreased to o10% of
that in the wild-type mice (data not shown). We then established
metastatic mouse models using B16F10-Luc2 melanoma and 4T1Luc2 breast cancer cells in these mice. Ten days after intravenous
tumor cell inoculation, in vivo bioluminescent imaging showed that
the signals of lung metastasis in KLF4-knockout (KLF4− / −) groups
were much lower than those in the control (KLF4+/+) groups in
both models (Supplementary Figure S1A). Two weeks after tumor
inoculation, mice were sacriﬁced and a signiﬁcantly decreased
incidence of lung metastasis was found in the KLF4− / − groups
(Supplementary Figure S1B). Flow cytometric analysis showed that
the percentage of MDSCs in bone marrow of the KLF4− / − group
was almost the same as the KLF4+/+ group in both of the two
metastatic models. In addition, although MDSCs were reduced in
spleen and lung after KLF4 was knocked out in these two models,
the differences between the KLF4− / − and KLF4+/+ groups were not
statistically signiﬁcant (data not shown).
Note that KLF4 deﬁciency was systemic in the above mentioned
mouse models. To exclusively investigate whether the KLF4knockout effect on tumor metastasis was contributed by bone
marrow KLF4, we performed the same experiments in the B16F10Luc2 melanoma metastatic model using chimeric mice that had
received bone marrow cells from B6 Rosa26CreER/KLF4(lox+/+)/βactin-EGFP+ donor mice. Similar with the systemic KLF4-knockout
mice, average bioluminescence intensity was decreased from 9.31
(±1.92) × 103 photons/s in the lung of control mice to 2.86
(±1.34) × 103 photons/second in the lung of mice with bone
marrow KLF4 knockout induced by TAM (Figure 1a, Po0.05).
Consistently, drastically decreased numbers of pulmonary metastatic nodules were found in the KLF4− / − group when compared
with the KLF4+/+ group (Figure 1b) and metastatic area was also
reduced upon KLF4 deﬁciency in bone marrow (Figure 1c).
Similarly, there were still no signiﬁcant changes of MDSCs in bone
marrow, spleen and lung after KLF4 knockout in the bone marrow
(data not shown), even though the percentages of MDSCs in the
lung were markedly reduced (Supplementary Figure S2A, P = 0.165).
MDSCs are heterogeneous. It was recently reported that a
subset of MDSCs characterized by CD11b+Gr-1+CD115+ was
preferentially recruited to the lung through the CCL2/CCR2
signaling pathway, resulting in facilitation of pulmonary metastasis of mammary tumor.18 We therefore postulated that KLF4 may
only regulate a speciﬁc subpopulation of MDSCs, such as CCR2+
MDSCs, leading to compromised lung metastasis in our studies.
Indeed, in the B16F10 chimeric metastasis model, the CCR2+
MDSC subset decreased from 2.41 (±0.21)% to 0.86 (±0.25)% in
lung (Figure 1d, Po 0.05), but not in spleen (Supplementary
Figure S2B, P = 0.057) or bone marrow (data not shown).
Consistent with these results in the B16F10 model, CCR2+ MDSCs
in lung (Supplementary Figure S3A, P o 0.001), but not in spleen
or bone marrow (data not shown), were also signiﬁcantly reduced
in the 4T1 metastatic model. Collectively, these data suggested
Oncogenesis (2014), 1 – 7

that KLF4 in bone marrow regulated the pulmonary recruitment of
CCR2+ MDSCs, and decreased CCR2+ MDSCs reduced tumor lung
metastasis.
KLF4 deﬁciency in bone marrow was associated with signiﬁcantly
decreased numbers of ﬁbrocytes and myoﬁbroblasts in metastatic
lung
MDSCs are well known for their immunosuppressive functions
under different pathological conditions including cancer
development.19 As discussed above, KLF4 knockout had limited
effects on the recruitment of the whole population of MDSCs, but
signiﬁcantly reduced the numbers of CCR2+ MDSC subset in lung.
It suggested that the signiﬁcantly reduced lung metastasis after
bone marrow KLF4 knockout was contributed by other factors
beyond the immunosuppressive function of CCR2+ MDSCs.
Recently it was reported that MDSCs had a high potential to
differentiate into ﬁbrocytes.6 As mesenchymal cells that arise from
monocyte precursors, ﬁbrocytes have both the inﬂammatory
features of macrophages and the tissue remodeling properties of
ﬁbroblasts.20 Circulating ﬁbrocytes can trafﬁc to lungs and
differentiate into ﬁbroblasts,21 the precursors of myoﬁbroblast
that are crucial tumor stromal component.22 Therefore, there was
an intriguing possibility that the CCR2+ MDSCs exerted their ability
of promoting metastatic tumor growth mostly by adopting a
ﬁbrocyte fate after they were recruited to lung. To test this, we ﬁrst
used B16F10 chimeric metastasis model. As the chimeric mice
received EGFP-expressing bone marrow cells, we used COL1A1+
CD45+CD11b+EGFP+ and CD11b+α-SMA+EGFP+ to identify bone
marrow-derived ﬁbrocytes and myoﬁbroblasts, respectively. The
peripheral blood monocytes and lung single cells of the chimeric
mice were examined by ﬂow cytometry. As shown in Figure 2a, the
percentage of ﬁbrocytes in peripheral blood monocytes dropped
from 2.50 (±0.32) % in the KLF4+/+ group to 0.63 (± 0.40) % in the
KLF4− / −group (Figure 2a, Po0.05). Although the percentage of
ﬁbrocytes and myoﬁbroblasts in the lung was similar between the
two groups (KLF4+/+ 2.54( ±0.28) % vs KLF4− / − 1.67(± 0.29) % for
ﬁbrocytes, P = 0.10, KLF4+/+ 17.03( ±1.15) % vs KLF4− / − 16.22(±
0.52) % for myoﬁbroblasts, P = 0.60), the total cell number of
COL1A1+CD45+CD11b+ EGFP+ and CD11b+α-SMA+EGFP+ cells in
the KLF4− / −group decreased by 64.30 and 64.34%, respectively
(Figure 2b). In parallel with these observations, the immunoﬂuorescent staining of lung sections showed that the numbers of
COL1A1+EGFP+ and α-SMA+EGFP+ double positive cells were
signiﬁcantly reduced in the KLF4− / − group when compared to
those in the KLF4+/+ group (Figures 2c and d). Consistently, in the
4T1 metastatic model, decreased populations of ﬁbrocytes
(COL1A1+CD45+CD11b+) were also observed in peripheral blood
monocytes and lung (Supplementary Figure S3B and S3C,
Po0.001 and Po0.01). Together, these ﬁndings supported our
hypothesis that CCR2+ MDSCs are not only preferentially recruited
to target organs to prepare for metastatic seeding, but also boost
metastatic tumor growth by adopting a ﬁbrocyte fate. In addition,
KLF4 regulates both of these two progresses.
KLF4 ablation in CCR2+ MDSCs reduced pulmonary metastasis that
was associated with decreased numbers of ﬁbrocytes
To exclude the effect of KLF4-mediated development of MDSCs
and to test the direct effect of KLF4-regulated ﬁbrocyte generation
from CCR2+ MDSCs on tumor metastasis, a cause-effect study was
performed. We sorted this speciﬁc MDSC subset from the lungs of
B6 Rosa26CreER/KLF4 (ﬂox+/+)/β-actin-EGFP+ mice bearing B16F10
melanoma, mixed with B16F10 tumor cells, and then injected
wild-type mice with the mixture intravenously, followed by
tamoxifen (TAM) injection to induce KLF4 knockout (Figure 3a).
In the control group, mice only received B16F10 tumor cells, but
still intraperitoneally injected with TAM or sunﬂower seed oil as
the control. At day 7 after tumor cell inoculation, mice were
© 2014 Macmillan Publishers Limited
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Figure 1. KLF4 deﬁciency in mouse bone marrow drastically reduced lung metastasis that was accompanied by decreased recruitment of CCR2+
MDSCs in the lung. (a) Six-week old C57BL/6 (B6) wild-type mice (The Jackson Laboratory, Bar Harbor, ME, USA) were lethally irradiated (900 rad)
and then transplanted with bone marrow cells (1.0 × 106 cells per recipient mouse) from B6 Rosa26CreER/KLF4 (ﬂox+/+)/β-actin-EGFP mice, which
were generated by crossing tamoxifen-inducible RosaCreER mice (01XAB, NCI) with KLF4 (ﬂox) mice (029877-Mu, MMRRC) and β-actin-EGFP mice
(The Jackson Laboratory). Four weeks later, KLF4 knockout of chimeric mice was induced by daily intraperitoneal injection of tamoxifen (TAM,
Sigma-Aldrich, St Louis, MO, USA; 50 mg/kg) for ﬁve consecutive days, followed by intravenous injection of B16F10-Luc2 tumor cells (Caliper Life
Sciences, Middlesex, MA, USA). Sunﬂower seed oil (Sigma-Aldrich) was used as control. These mice were then monitored by IVIS Spectrum
Fluorescence and Bioluminescence Imaging System (Caliper Life sciences) to detect the signals of pulmonary metastasis. Results of
representative control (KLF4+/+) and TAM-induced (KLF4− / −) mice at day 10 after tumor cell inoculation were shown (n = 8, Po0.05). (b)
Representatives of lung macrometastases from the chimeric mice as described in a were shown. (c) Left, representative HE stained lung sections
with red arrows pointing the metastatic lesions were displayed (scale bars = 100 μm). Right, percentages of metastatic areas in control and TAMinduced chimeric mice were quantiﬁed. (d) Lungs were minced into small fragments (o1 mm3) and digested in 10 ml of dissociation solution
(RPMI 1640 medium supplemented with Collagenase type I (200 U/ml) and DNase I (100 μg/ml)) for 60 min at 37 °C. Lung-inﬁltrating immune
cells were further puriﬁed using Percoll (Sigma-Aldrich) according to the manufacturer’s instructions. The cells with intermediate Ly6G (clone
RB6-8C5, eBiosciences, San Diego, CA, USA) signals (Ly6GInt) were gated (left) followed by further ﬂow cytometry analysis (right) using CD11b
(clone M1/70, eBiosciences) and CCR2 (R&D, Minneapolis, MN, USA) antibodies. The ﬂow cytometry were performed and data were analyzed
using FACSAria II (BD Biosciences, San Jose, CA, USA). Representative dot plots in each group were shown (n = 8). Mean ± s.e.m., ***Po 0.001.

sacriﬁced. The gross view and hematoxylin and eosin staining of
the lung in the control group showed that there was no difference
in the incidence of lung metastasis between the mice administrated with TAM or sunﬂower seed oil (data not shown). However,
the pulmonary metastatic nodules in the KLF4− / − and control
groups were drastically fewer than those in the KLF4+/+ group. The
percentages of lung metastatic areas in KLF4− / − (2.64 ( ± 0.16)%)
and control group (2.87 ( ± 0.21)%) were also signiﬁcantly lower
© 2014 Macmillan Publishers Limited

than those in the KLF4+/+ group (11.71 ( ± 0.88)%; Figure 3b). Note
that KLF4 deﬁciency in CCR2+ MDSCs led to similar metastatic
areas in KLF4− / − group as in the control group. The results
demonstrated that CCR2+ MDSCs did facilitate the seeding and
growth of pulmonary metastatic nodules in a KLF4-dependent
manner. Because the transplanted CCR2+ MDSC cells also carried
the EGFP marker, we examined their differentiation in the lung by
immunoﬂuorescent staining of lung cryosections with COL1A1
Oncogenesis (2014), 1 – 7
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Figure 2. LF4 deﬁciency in bone marrow was associated with signiﬁcantly decreased numbers of ﬁbrocytes and myoﬁbroblasts in metastatic lung. (a) The peripheral blood monocytes (PBMCs) from the chimeric mice as described in Figure 1 were isolated using Histoplaque
(Sigma-Aldrich) according to the manufacturer’s instructions. EGFP-expressing PBMCs were stained and gated by biotin-conjugated mouse
Collagen Type I alpha1 antibody (COL1A1; Rockland, Gilbertsville, PA, USA; left) and further analyzed using CD45 (clone 30-F11, eBiosciences)
and CD11b antibodies (right) by ﬂow cytometry. Representative dot plots were shown (n = 8, Po0.05). (b) Lung-inﬁltrating immune cells were
stained with biotin-conjugated mouse COL1A1, rabbit anti-mouse α-SMA (Millipore, Billerica, MA, USA), CD11b and CD45 antibodies and then
examined using ﬂow cytometry. Quantiﬁcations of the total number of COL1A1+CD45+CD11b+EGFP+ cells (left) and CD11b+α-SMA+EGFP+
cells (right) in lung were shown based on cell counting and ﬂow cytometry data. (c and d) Representative immunoﬂuorescence staining of
lung tissues with rabbit anti-mouse COL1A1 (Rockland; 1:200, scale bars = 100 μm) and α-SMA (1:200, scale bars = 50 μm). COL1A1+EGFP+ and
α-SMA+EGFP+ double positive cells (yellow arrows) within dotted lines encircling metastatic lesions were counted for every ﬁve high power
ﬁelds (HPF) and compared. Mean ± s.e.m., *P o0.05, **Po 0.01, ***P o0.001.

and α-SMA antibodies. The results showed that although there was
no difference in the total number of EGFP+ cells between the
KLF4+/+ and KLF4− / − group (data not shown), COL1A1+EGFP+ cells
decreased from 6.20 ( ±0.66)% in the KLF4+/+ mice to 1.6 (±0.51)%
in KLF4 deﬁcient mice (Figure 3c, Po0.001). Similarly, α-SMA+EGFP+
cells also decreased in KLF4− / − mice (KLF4+/+ 4.6 (±0.68)% versus
KLF4− / − 1.4 (±0.40)%, Po0.01, Figure 3c), which further supported
Oncogenesis (2014), 1 – 7

our speculation that KLF4 regulates the differentiation of CCR2+
MDSCs after they are recruited to the lung in vivo.
KLF4 gene expression was tightly linked with that of FSP-1 in
ﬁbrocyte generation from MDSCs
To elucidate the underlying molecular mechanism, we proceeded to
examine the role of KLF4 in ﬁbrocyte generation from MDSCs in vitro.
© 2014 Macmillan Publishers Limited
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Figure 3. KLF4 ablation in CCR2+ MDSCs reduced pulmonary metastasis that was associated with decreased numbers of ﬁbrocytes.
(a) Rosa26CreER/KLF4 (ﬂox+/+)/β-actin-EGFP mice were inoculated under the dorsal skin with 5 × 105 B16F10-Luc2 cells. Three to four weeks
later, CCR2+ MDSCs were sorted from the lung of the tumor-bearing mice, mixed with B16F10 melanoma cells and injected into WT mice
intravenously, followed by induction of KLF4 knockout as described in Figure 1. The mice in the control group were injected with B16F10
melanoma cells only, but were still treated with tamoxifen or sunﬂower seed oil. Mice were sacriﬁced 1 week later for various analyses. (b) Left,
representative lung macrometastases (top) and hematoxylin and eosin stained sections with red arrows pointing metastatic lesions (bottom)
from the mice as described in a were shown (scale bars = 100 μm). Quantiﬁcation of percentages of metastatic areas in each group was
showed on the right. (c) and (d) Representative IF staining of lung tissues with COL1A1 (1:200) and α-SMA (1:200). COL1A1+EGFP+ and αSMA+EGFP+ double positive cells (yellow arrows) within dotted lines circling metastatic lesions were counted for every ﬁve HPF and compared
(scale bars = 50 μm). Mean ± s.e.m., **Po 0.01, ***Po 0.001. HPF, high power ﬁelds; IF, immunoﬂuorescent; NS, not signiﬁcant; WT, wild type.

Splenocytes from Rosa26CreER/KLF4 (ﬂox+/+) mice were puriﬁed
followed by ﬁbrocyte generation assay with recombinant murine
interleukin-13 and macrophage colony-stimulating factor as
previously described.23 4-OH TAM was used to induce KLF4
knockout. Three days after the cytokine treatment, the cells were
stained and the numbers of ﬁbrocytes per 1 × 105 splenocytes in
each group were counted. While there were 58 ± 7 ﬁbrocytes per
1 × 105 splenocytes in the control group, the number of ﬁbrocytes
decreased to 5 ± 2 ﬁbrocytes per 1 × 105 splenocytes in the presence
of 5 μM 4-OH TAM (Figure 4a). In the presence of 10 μM of 4-OH, there
were no ﬁbrocytes generated from splenocytes (data not shown).
Quantitative reverse transcriptase–PCR analysis revealed that expression levels of KLF4 and FSP-1 were signiﬁcantly elevated after the
application of interleukin-13 and macrophage colony-stimulating
© 2014 Macmillan Publishers Limited

factor, and KLF4 knockout induced by 4-OH TAM correlated with
signiﬁcant downregulation of FSP-1 expression (Figure 4b). Consistently, the expression levels of FSP-1 in bone marrow, spleen and
lung of the chimeric metastatic model were all decreased upon KLF4
knockout (Supplementary Figure 4), accompanied with deceased
lung metastasis. FSP-1 is a member of S100 superfamily of calciumbinding proteins whose expression level is strongly associated with
an aggressive metastatic phenotype and worse prognosis for
patients with various malignancies.24 The causative role of FSP-1 in
tumor metastasis has been well established in literature.24,25 Given
the fact that FSP-1 has a speciﬁc expression in ﬁbroblasts and is also
found in more than 90% of monocytes of the host immune system,26
it is quite possible that there is a lineage link between the two very
different cell types. Our in vivo data has shown that the populations
Oncogenesis (2014), 1 – 7
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Figure 4. KLF4 gene expression was tightly linked with that of FSP-1 in ﬁbrocyte generation from MDSCs. (a) Splenocytes from Rosa26CreER/
KLF4 (ﬂox+/+) mice were puriﬁed and subjected to ﬁbrocyte generation using a recently developed approach with the application of murine
interleukin (IL)-13 (50 ng/ml) and macrophage colony-stimulating factor (25 ng/ml).23 4-OH tamoxifen (4-OH TAM, Sigma-Aldrich) was used to
induce KLF4 knockout in vitro and 100% ethanol as a control. Three days later, the cells were stained with Hema 3 staining kit (Fisher Scientiﬁc,
Waltham, MA, USA) and the numbers of ﬁbrocytes per 1 × 105 splenocytes in each group were counted. Left, representative photographs of
ﬁbrocytes generated from splenocytes (red arrows) were shown. Right, the number of ﬁbrocytes per 1 × 105 splenocytes in each group was
counted and compared (n = 5). (b) The total RNA of ﬁbrocytes generated as described in a were extracted using Trizol Reagent (Invitrogen,
Grand Island, NY, USA) according to the manufacturer’s instructions. First-strand cDNA synthesis and quantitative reverse transcriptase–PCR
(qRT–PCR) were performed as described previously.15 The relative expression levels of KLF4 and FSP-1 were normalized to that of GAPDH.
Primer sequences for qRT–PCR were listed in Supplementary Table S1. (c) Four different MDSC subsets in mouse splenocytes were gated using
CD11b and Ly6G antibodies (left) and then sorted for qRT–PCR (middle) and ﬁbrocyte generation assays (right). (d) Left, KLF4 bound to the
promoter region of FSP-1 by the chromatin immunoprecipitation assay as we previously described28 using NIH 3T3 cells (ATCC, Manassas, VA,
USA). Two KLF4 antibodies (KLF4-1 antibody from our laboratory29 and KLF4-2 antibody from Genespin (Milano, Italy)) were used to
precipitate DNA–protein complexes followed by PCR to amplify a 135-bp fragment in the FSP-1 promoter. Normal rabbit immunoglobulin G
(IgG, Santa Cruz Biotechnology, Dallas, TX, USA) was used as a negative control. The PCR primers were listed in Supplementary Table 1. Right,
KLF4 overexpression increased the promoter activities of FSP-1 by transient transfection and dual luciferase assay. A ~ 2.3 kb mouse FSP-1
promoter region was ampliﬁed (MGI: 1330282, nucleotide position − 1104 to 1224) using the primers listed in Supplementary Table 1. It was
cloned into pGL2 basic vector (Promega, Sunnyvale, CA, USA) and conﬁrmed by sequencing. FSP-1 promoter luciferase reporter and KLF4overexpressing construct were co-transfected into NIH 3T3 cells using TurboFect (Thermo Scientiﬁc, Waltham, MA, USA) according to the
manufacturer’s instructions. The empty pGL2 vector was used as a control. Two days after transfection, the cells were lysed and the effect of
KLF4 overexpression on FSP-1 promoter activity was assessed using the dual luciferase assay system (Promega). Mean ± s.e.m., *P o 0.05,
**P o 0.01.

of CCR2+MDSCs, ﬁbrocytes and myoﬁbroblasts were highly correlated, suggesting that ﬁbrocytes are the key to connect the host
immune cells with ﬁbroblasts in the tumor microenvironment by
carrying the expression/function of FSP-1.
Oncogenesis (2014), 1 – 7

To further test our hypothesis, we sorted four different subsets
of MDSCs from murine splenocytes based on CD11b and Ly6G
signals (Figure 4c) and performed quantitative PCR analysis and
ﬁbrocyte generation assay. In agreement with our speculation, the
© 2014 Macmillan Publishers Limited
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highest expression levels of KLF4, FSP-1 and CCR2 coexisted in
CD11b+Ly6Gint MDSCs (namely CCR2+MDSCs, P2 in Figure 4c)
among all the MDSC subsets, and this subpopulation showed the
most efﬁcient ﬁbrocyte generation as well (Figure 4c). To examine
the potential regulation of FSP-1 transcription by KLF4, we ﬁrst
performed chromatin immunoprecipitation assay using two
different KLF4 antibodies to examine the direct binding of KLF4
with the FSP-1 promoter. As shown in the left panel of Figure 4d,
both KLF4 antibodies but not control immunoglobulin G pulled
down a fragment in the FSP-1 promoter region as ampliﬁed by
PCR. We also generated a ~ 2.3 kb FSP-1 promoter luciferase
reporter construct and performed dual luciferase assays. As shown
in the right panel of Figure 4d, overexpression of KLF4 tripled the
FSP-1 promoter activity when compared with that of the vector
control. Together, these data suggest a direct regulation of FSP-1
expression by KLF4 at the transcription level in the process of
ﬁbrocyte generation from CCR2+ MDSCs.
Collectively, our data suggest that KLF4 in bone marrow
promotes tumor metastasis by regulating the recruitment of
CCR2+ MDSCs, likely in a CCL2/CCR2-dependent manner because
KLF4 regulates CCR2 expression.27 In addition, once CCR2+ MDSCs
are recruited to the lung, KLF4 further regulates their differentiation
into ﬁbrocytes resulting in increased metastatic tumor growth
probably dependent on KLF4-mediated FSP-1 expression. This
ﬁnding uncovered, to our knowledge, a novel mechanism whereby
FSP-1 promotes tumor metastasis by ﬁbrocyte generation from
MDSCs. One limitation of our study is that we only used KLF4
deﬁcient mouse models. Future experiments with transgenic mice
overexpressing KLF4 in bone marrow will further conﬁrm our
observations. In addition, to conﬁrm our hypothesis that KLF4
promotes tumor metastasis in a FSP-1 dependent manner, future
experiments will be performed to test whether ectopic expression
of KLF4 can rescue FSP-1 knockout-induced phenotypes of tumor
metastasis. However, in Fsp-1-Cre/KLF4 (ﬂox+/+) mice, KLF4
deﬁciency was correlated with drastic downregulation of FSP-1
(data not shown). These results not only conﬁrmed regulation of
FSP-1 by KLF4, but also supported our overall hypothesis. Finally,
further studies are needed to fully characterize the mechanism
whereby KLF4 regulates FSP-1 transcription.
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